Tracer has developed a proprietary platform for tumor-informed circulating-tumor DNA detection using digital PCR.

Labcorp will acquire portions of the lab's clinical and women's health testing businesses, while MAWD will continue to provide anatomic and other pathology services.

Last week, readers were most interested in a story about Gates Foundation Awards to Detact Diagnostics to further develop a POC system and assays to detect infectious diseases.

NEW YORK – Bio-Techne announced on Thursday that it has inked a distribution deal with MedSanTek to distribute Bio-Techne products in Turkey.

The deal involves the implementation in Limbach Group labs of Noul's automated MiLab instrument that uses microscopy and AI-developed algorithms to analyze samples.

The new Cobas 6800/8800 systems 2.0 enhances throughput and run flexibility and enables sample prioritization.

The funding will support the development of the AmplifiDx Dx 100 Platform for use with a nucleic acid amplification test for respiratory infections.

The company has requested a hearing and paid a $20,000 fee to delay its delisting determination until Jan. 9, 2025.

The firm also has plans for tests beyond sepsis, including for cardiac events and other conditions that are commonly treated in acute care settings.

The PD-L1 IHC 28-8 PharmDx test is used to provide information on PD-L1 expression as a biomarker for patient response to therapies containing anti-PD-1 antibodies.

The US Food and Drug Administration granted clearances to tests for infectious diseases, drug resistances, and chronic diseases, among other clearances.